LGND Q2 2024 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+57.5% YoY

Gross Profit

$57M136.9% margin

Operating Income

-$19M-46.0% margin

Net Income

-$52M-125.0% margin

EPS (Diluted)

$-2.88

QoQ Revenue Growth

+34.1%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$11M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$866M

Total Liabilities

$91M

Stockholders' Equity

$775M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$26M	+57.5%
Gross Profit	$57M	$25M	+130.2%
Operating Income	-$19M	-$2M	-863.2%
Net Income	-$52M	$2M	-2366.9%

Revenue Segments

Royalty

$23M32%

Intangible Royalty Assets

$23M31%

Kyprolis

$9M12%

Material Sales, Captisol

$8M10%

Rylaze

$3M4%

Evomela

$3M4%

Teriparatide Injection

$2M3%

Royalty, Other

$2M3%

Financial Royalty Assets

$559,0001%